Introduction Cryptogenic stroke (CS) represents one-third of ischemic strokes. Atrial fibrillation (AF) can be detected in up to 30% of CS. Therefore, there is a clinical need for predicting AF to guide the optimal secondary prevention strategy. The evidence about the role of advanced echocardiography, including left atrial 3D index volume and left atrial strain (LAS) techniques, to predict underlying AF in this setting is lacking. Methods From April 2019 to November 2021 seventy-eight consecutive patients with ischemic stroke or transient ischemic attack with ABCD2 scale ≥4 of unknown etiology were prospectively recruited. Echocardiography was performed during admission. All patients underwent 15 days wearable Holter monitoring. The primary outcome measure was AF detection during follow-up. Results Twenty -two patients (28%) developed AF. Patients in the AF group were older (81±6.3 vs 76.5±7.8 years; p=0.012). Left atrial (LA) diastolic indexed volume was higher in AF group (37.2±12.8 vs 29.7±11 ml/m2 p=0.01). 3D LA indexed volume were also higher in patients with AF (41.4±14 vs 32.2±10 ml/m2 p=0.009). LAS reservoir, LAS conduct and LAS contraction (LASct) were significantly lower in patients with AF (19±5.6 vs 32±10.3%; 9±4.5 vs 15±7.6; 10±5.3 vs 17±6.4, respectively, all p<0.001). On multivariate analysis LASct <13.5% and LA 3D indexed volume >44.5 ml/m2 were independent predictors of AF (OR 10.9 [95% CI 1.09–108.2], p=0.042) (Table 1, Figure 1) Conclusion LASct <13.5% and LA 3D indexed volume >44.5 ml/m2 are independent predictors of underlying AF in patients with CS. Our results demonstrate the usefulness of advanced echocardiography in this challenging clinical setting. Funding Acknowledgement Type of funding sources: Other. Main funding source(s): Spanish Society of Cardiology
Funding Acknowledgements Type of funding sources: None. Introduction Both aortic regurgitation (AR) and mitral regurgitation (MR) produce left ventricular (LV) volume overload (1). Current prognostic assessment of AR does not include the presence and magnitude of MR. Therefore, in patients with concomitant AR and MR we might be underestimating the future need of valve replacement surgery. Cardiac magnetic resonance (CMR) is a very precise tool to quantify LV volumes together with aortic and mitral regurgitant volumes. Combining data from cine and phase contrast sequences it is possible to obtain a set parameter: total regurgitant fraction (TRF). Purpose To describe the prognostic value of TRF in patients with concomitant AR and MR. Methods Patients with concomitant AR and MR with CMR studies were retrospectively recruited in three tertiary hospitals. Cases of at least moderate AR and any grade of MR were included in the analysis. Patients with indication of aortic valve surgery (symptoms, severe LV dilatation or reduced LV eyection fraction) in the moment of the CMR were excluded. Aortic regurgitant fraction (ARF) was calculated from the phase constrast data as the ratio of AR volume and LV forward volume. Mitral regurgitant Fraction (MRF) was calculated from the cine sequences as the ratio of the MR volume and the LV stroke volume (LVSV) . TRF was calculated as the ratio of mitral plus aortic regurgitant volumes and the LVSV (MRV+ARV/LVSV) Results 35 cases were analyzed, with a mean follow up period of 40 months. 9 patients developed indications of aortic valve surgery. TRF had an area under curve (AUC) to predict aortic valve surgery of 0.82, in opposite to aortic regurgitant fraction (ARF) which had an AUC of 0.75 (Figure 1) The optimum cutoff value of TRF and ARF to predict the need of surgery in our series were 38% and 27%, respectively. After 3 years of follow up 53% of patients with TRF > 38% had to be intervened (Figure 2A). In contrast, 32% of patients with ARF >27% had to be intervened (Figure 2B) Conclusion MR presence increases volume overload in patients with moderate or severe AR. TRF is a promising parameter to predict the need of aortic valve surgery in this patients
Funding Acknowledgements Type of funding sources: None. Background In patients admitted for heart failure (HF) with reduced left ventricular ejection fraction (LVEF) and a concomitant high-rate supraventricular tachyarrhythmia (SVT) it is challenging to predict LVEF recovery after heart rate control and distinguish tachycardia-induced cardiomyopathy (TIC) from dilated cardiomyopathy (DC). The role of cardiac magnetic resonance (CMR) and the electrocardiogram (ECG) in this setting remains unsettled. Methods Forty-three consecutive patients admitted for HF due to high-rate SVT and LVEF <50% undergoing CMR in the acute phase were retrospectively included. Those who had LVEF >50% at follow up were classified as TIC and those with LVEF <50% were classified as DC. Clinical, laboratory, CMR and ECG findings were analyzed to predict LVEF recovery. Results Twenty-five (58%) patients were classified as TIC. Patients with DC had wider QRS (121.2 ± 26 vs 97.7 ± 17.35 ms; p = 0.003). On CRM the TIC group presented with higher LVEF (33.4 ± 11 vs 26.9 ± 6.4% p = 0.019) whereas late gadolinium enhancement (LGE) was more frequent in DC group (61 vs 16% p = 0.004). On multivariate analysis, QRS duration ≥100 ms (p = 0.027), LVEF < 40% on CMR (p = 0.047) and presence of LGE (p = 0.03) were identified as independent predictors of lack of LVEF recovery. Furthermore, during clinical follow-up (median 60 months) DC patients were admitted more frequently for HF (44% vs 0%; p < 0.001) than TIC patients (Figure 1). Conclusion In patients with reduced LVEF admitted for HF due to high-rate SVT, QRS duration ≥100 ms, LVEF <40% on CMR and presence of LGE are independently associated with lack of LVEF recovery and worse clinical outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.